Suche
Filter by content type
Filter by content year
Filter by category
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
Oktober 23, 2023 - … pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, … pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, … pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, …
BioNTech to Present Clinical and Preclinical Data Updates Across Multiple Immuno-Oncology Programs at 2023 SITC Annual Meeting
Oktober 31, 2023 - … pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, … pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, … pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, …
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
Juni 2, 2023 - … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit …
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
Juni 29, 2023 - … global pharmaceutical collaborators, including DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, … global pharmaceutical collaborators, including DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, … global pharmaceutical collaborators, including DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, …
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
Dezember 21, 2023 - … pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, … pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, … pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, …
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
Oktober 19, 2023 - … pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, … pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, … pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, …
BioNTech präsentiert auf der SITC-Jahrestagung 2023 aktuelle klinische und präklinische Daten aus mehreren Immuno-Onkologie-Programmen
Oktober 31, 2023 - … pharmazeutischen Industrie, darunter Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … pharmazeutischen Industrie, darunter Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … pharmazeutischen Industrie, darunter Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), …
BioNTech präsentiert positives Daten-Update aus der Phase-1/2-Studie mit dem CAR-T-Zelltherapiekandidat BNT211 bei fortgeschrittenen soliden Tumoren auf dem ESMO-Kongress 2023
Oktober 23, 2023 - … pharmazeutischen Industrie, darunter Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … pharmazeutischen Industrie, darunter Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … pharmazeutischen Industrie, darunter Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), …
BioNTech und OncoC4 präsentieren positive Phase-1/2-Daten für Antikörperkandidaten BNT316/ONC-392 bei schwer behandelbarem nicht-kleinzelligen Lungenkarzinom auf ASCO-Jahrestagung
Juni 2, 2023 - … (ein Unternehmen der Roche Gruppe), Regeneron, Genevant, Fosun Pharma und Pfizer. Weitere Information finden Sie … (ein Unternehmen der Roche Gruppe), Regeneron, Genevant, Fosun Pharma und Pfizer. Weitere Information finden Sie … (ein Unternehmen der Roche Gruppe), Regeneron, Genevant, Fosun Pharma und Pfizer. Weitere Information finden Sie …
BioNTech und OncoC4 starten zulassungsrelevante Phase-3-Studie mit BNT316/ONC-392-Programm bei metastasiertem, nicht-kleinzelligem Lungenkarzinom
Juni 29, 2023 - … aus der pharmazeutischen Industrie, darunter DualityBio, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … aus der pharmazeutischen Industrie, darunter DualityBio, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … aus der pharmazeutischen Industrie, darunter DualityBio, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), …